Gene regulation by BCL3 in a cervical cancer cell line
Author
dc.contributor.author
Maldonado, Vilma
Author
dc.contributor.author
Espinosa, M.
Author
dc.contributor.author
Pruefer, F.
Author
dc.contributor.author
Patiño, N.
Author
dc.contributor.author
Ceballos Cancino, G.
Author
dc.contributor.author
Urzúa, U.
Author
dc.contributor.author
Juretic Díaz, Nevenka Militza
Author
dc.contributor.author
Meléndez Zajgla, Jorge
Admission date
dc.date.accessioned
2019-03-11T13:00:15Z
Available date
dc.date.available
2019-03-11T13:00:15Z
Publication date
dc.date.issued
2010
Cita de ítem
dc.identifier.citation
Folia Biologica (Praha) 56, 183-193 (2010)
Identifier
dc.identifier.issn
25337602
Identifier
dc.identifier.issn
00155500
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165074
Abstract
dc.description.abstract
BCL3 is a putative proto-oncogene deregulated in haematopoieitic and solid tumours. It has been suggested that its oncogenic effects could be mediated, at least in part, by inducing proliferation and inhibiting cell death. To provide more insight into the mediators of these effects, we used an unbiased approach to analyse the mRNA expression changes after knocking-down BCL3 using specific shRNAs. One hundred eighty genes were up-regulated and sixty-nine genes were down-regulated after knocking down BCL3. Function analyses showed enrichment in genes associated with cellular growth and proliferation, cell death and gene expression. We found that STAT3, an important oncogene in human cancer, was the central node of one of the most significant networks. We validated STAT3 as a bona fide target of BCL3 by additional interference RNA and in silico analyses of previously reported lymphoma patients.